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Gene therapy is such a simple and
appealing idea. If you have the
wrong version of a given gene,
you just exchange it for the
correct version, and you’re cured.
In practice, it has been anything
but simple. Researchers had to
make pacts with any number of
devils, including retroviruses, in
their attempts to smuggle the
required genes into human cells.
As yet, they simply don’t have a
gene vector that is both efficient
and completely controllable.
Therefore, the history of gene
therapy from the very first clinical
trial in 1990 to this day has been a
rollercoaster. One particularly
discouraging low point was the
death of 18-year-old Jesse
Gelsinger in 1999, whose immune
system overreacted to the
invasion of the viral vector. There
followed a much-needed high,
when Alain Fischer at the Necker
Hospital in Paris succeeded in
curing the X-linked severe
combined immune deficiency 
(X-SCID) of ten so-called bubble
babies, using a retrovirus coaxed
into delivering the missing gene
into the children’s bone marrow
cells. This was the first ever
example showing that gene
therapy can actually cure a human
disease.
By the beginning of this year,
however, this study had suffered a
severe setback when the second
of the 10 children treated was
diagnosed with leukemia. While
the researchers had been aware
that there was a small risk that the
gene transfer might activate an
oncogene, the observed frequency
of cases suggests that the vector
has a preference for inserting the
gene in a place where it can cause
cancer. Clearly, researchers need
to return to the bench in order to
find out why the inserted gene has
a tendency to touch down in the
wrong place.
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In spite of some setbacks, gene therapy trials continue and the UK
government is putting in place plans to bring the potential power of
genetics into mainstream public heath care through its National Health
Service. Michael Gross reports. 
Britain’s National Health Service
(NHS) is famous for being cheaper
than its continental European
counterparts. The downside is that
more and more treatments are
either not available from the NHS,
or only available after long waiting
times. To patients who have
experienced the long wait, the
proposal to hitch up this slow
colossus with the fast-moving
research in genetics might appear
a little bit puzzling.
On closer inspection, the White
Paper [1] basically acknowledges
that there has been revolutionary
change in genetics, and that the
public sector health care needs to
do something to remain at least in
touch with progress (if not exactly
a world leader, as the paper
grandiosely claims). It rounds up a
variety of genetics-related issues,
which have very different
characteristics and political needs.
Some can be addressed with
legislation, others with money,
others again with getting people to
talk to each other.
The specific issues addressed in
the report include:
* Strengthening the capacities
for genetic testing with over £20
million for improved facilities, more
technicians and trainers, and
improved IT.
* More widespread availability of
genetic testing in the NHS,
including antenatal screening and
cancer prevention in patients at
risk of familial cancer.
* Spreading knowledge amongst
the NHS staff, i.e. by improved
training and life-long learning
infrastructure.
* Generating new knowledge,
including a pledge for £15 million
to fund ‘knowledge parks’, where
NHS, university, and industry
researchers can combine their
efforts, along with funds for a chair
in pharmacogenetics, and the gene
therapy grants mentioned in the
main text.
* ‘Ensuring public confidence’
addresses the most common
worries surrounding the new
genetics with a mixture of public
understanding programmes,
promises of controls and
safeguards, and legislation making
DNA theft illegal, an aim already
proposed by the government’s
Human Genetics Commission a
year earlier (Curr. Biol. (2002) 12,
R408).
While the White Paper shows
that the government is aware of
the opportunities and risks
brought about by new genetic
methods and knowledge, many
researchers will doubt whether its
proclaimed goal of making the
NHS ‘a world leader in genetics’
can be bought with such a small
budget. Spread out over the
population covered by the NHS,
£50 million disperse into less than
one pound per head. Contrast this
with the expenditure on the war in
Iraq, which has cost the British
taxpayers several billion pounds
so far, and you begin to realise
that there may be something
wrong with the number of zeroes
in the genetics budget. For cystic
fibrosis alone, a charity
specialising on this disease has
estimated the price tag for a
breakthrough therapy at £6 million.
At the end of the day, the
consumer using the NHS in a few
years’ time will probably be more
likely than today to be offered
genetic testing backed up with
competent advice. But for gene
therapy or pharmacogenetic
assessment, they will probably
have to wait a bit longer.




The mixed message of hope
and danger emanating from this
case is reflected in variable
enthusiasm for gene therapy
around the globe. In Germany,
where the research ministry has
cautiously supported such
research since 1994, Ärzte
Zeitung estimates that around 250
patients are currently undergoing
experimental treatment involving
gene transfer. All such trials must
be approved by the ‘Kommission
Somatische Gentherapie’, an
expert committee formed by the
scientific advisory board of the
federal chamber of physicians
(Bundesärztekammer). After the
bad news from Paris broke, the
committee halted all studies
involving retroviruses for a careful
reassessment of the risk situation.
By now it seems certain that most
of the studies will be continued.
Only one, which was to target
granulomatosis, is still blocked
indefinitely.
In the United States, a new
gene therapy trial targeting age-
dependent macula degeneration
has been given the go-ahead in
February. It will initially involve
around 50 patients. In Britain, a
smaller scale trial of X-SCID gene
therapy, similar to the one at
Paris, funded by the ‘Jeans for
Genes’ campaign, has been
carried out at Great Ormond
Street Hospital in London. It
reported its first cure in April 2002.
At the beginning of this year, the
study was suspended for a few
months, but is now set to
continue.
Meanwhile, the UK government
has published an official report
(‘White Paper’) on genetics,
entitled ‘Our inheritance - our
future: Realising the potential of
genetics in the NHS’ with plans of
incorporating recent advances in
genetics into the mainstream
healthcare offered by the National
Health Service (NHS). The paper,
prepared by the former Health
Secretary Alan Milburn and
presented by his successor John
Reid, comprises the search for
new treatments, including gene
therapy, alongside with enhanced
antenatal screening, genetics-
related counselling, knowledge
transfer measures, and legislation
against DNA theft (see sidebar).
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The paper pronounces with
cautious optimism that gene
therapy might become available
within five to ten years from now.
It pledges government investment
of £3 million for gene therapy
research targeting disorders
caused by mutations of a single
gene, and an extra £2.5 million,
spread out over five years, to
develop a gene transfer therapy
against cystic fibrosis, the most
common such disease in Britain. A
further £4 million (of £50 million for
the entire genetics initiative) are
earmarked to give NHS and other
public sector researchers access
to facilities where suitable vectors
for gene therapy can be
produced.
While researchers everywhere
have been sobered by the
leukemia cases and may in some
cases be forced to reconsider
their use of retroviral vectors, the
search for the right way of curing
the genes causing severe
disorders such as X-SCID and
cystic fibrosis goes on. Getting it
right will not be simple, and it will
probably be more expensive than
the UK government seems to
think. But it will be truly
revolutionary.
Michael Gross is a science writer in
residence at the school of
crystallography, Birkbeck College,






the UK’s latest media frenzy over
genetically modified (GM) foods
was triggered in precisely the
opposite way. It began with a
newspaper article by a former
minister on a subject for which he
was until very recently
responsible.
“Blair buried health warning on
GM crops, says sacked minister”
was the banner headline which
launched the piece by Michael
Meacher in The Independent on
Sunday. The former Environment
Minister criticised Prime Minister
Tony Blair for (allegedly)
contravening his own policy that
the debate should be conducted
on the basis of scientific evidence
rather than prejudice. Yet nothing
in the article supported that
allegation.
Meacher cited a claim that GM
technology “often involves
producing novel substances
which may provoke allergic
reactions”. In the real world, of
course, its major promise is in
deleting genes coding for
allergens. The only “scientific
evidence” cited by Meacher was
from experiments when a known
allergen gene was transferred
from brazil nuts to soya — which
then provoked adverse reactions
in subjects already known to be
allergic to brazil nuts.
Meacher also asserted that
Arpad Pusztai's “work on rats and
GM potatoes...was widely
rubbished in government circles
even though his paper had been
peer reviewed six times before
publication.” Given that Pusztai’s
claims five years ago of adverse
effects on growth and the immune
system have never appeared in a
peer-reviewed journal, this is a
travesty of reality. Even the paper
which he did co-author (on the
structure of the small intestine)
appeared against peer review
advice (Curr. Biol. (1999) 9, R794).
Among many other distortions,
Meacher quoted selectively from a
Royal Society report that GM
could “lead to unpredictable
harmful changes in the nutritional
state of foods”. Of course it could.
But as Lord May, president of the
society, said in The Independent
three days later, Meacher
“conspicuously fails to mention its
principal conclusion that there is
no scientific reason to doubt the
GM crops dancing to different tunes
Mediawatch: Parts of the British media are keeping up a campaign
against the introduction of genetically modified crops ahead of the
government’s assessment of the trial programme this autumn, often to
the detriment of the arguments, writes Bernard Dixon.
